@article{228a27eb00ca4407b0c29b3778556b43,
title = "The kinase chemogenomic set (KCGS): An open science resource for kinase vulnerability identification",
abstract = "We describe the assembly and annotation of a chemogenomic set of protein kinase inhibitors as an open science resource for studying kinase biology. The set only includes inhibitors that show potent kinase inhibition and a narrow spectrum of activity when screened across a large panel of kinase biochemical assays. Currently, the set contains 187 inhibitors that cover 215 human kinases. The kinase chemogenomic set (KCGS), current Version 1.0, is the most highly annotated set of selective kinase inhibitors available to researchers for use in cell-based screens.",
keywords = "Chemogenomic set, Drug discovery, Druggable genome, KCGS, Kinase inhibitor, Phenotypic screening, Protein kinase, Small molecules, Understudied kinase",
author = "Wells, {Carrow I.} and Hassan Al-Ali and Andrews, {David M.} and Asquith, {Christopher R.M.} and Axtman, {Alison D.} and Ivan Dikic and Daniel Ebner and Peter Ettmayer and Christian Fischer and Mathias Frederiksen and Futrell, {Robert E.} and Gray, {Nathanael S.} and Hatch, {Stephanie B.} and Stefan Knapp and Ulrich L{\"u}cking and Michael Michaelides and Mills, {Caitlin E.} and Susanne M{\"u}ller and Dafydd Owen and Alfredo Picado and Saikatendu, {Kumar S.} and Martin Schr{\"o}der and Alexandra Stolz and Mariana Tellechea and Turunen, {Brandon J.} and Santiago Vilar and Jinhua Wang and Zuercher, {William J.} and Willson, {Timothy M.} and Drewry, {David H.}",
note = "Funding Information: Funding: The Structural Genomics Consortium is a registered charity (no: 1097737) that receives funds from AbbVie; Bayer Pharma AG; Boehringer Ingelheim; Canada Foundation for Innovation; Eshelman Institute for Innovation; Genentech, Genome Canada through Ontario Genomics Institute (OGI-196); EU/EFPIA/OICR/McGill/KTH/Diamond Innovative Medicines Initiative 2 Joint Undertaking (EUbOPEN grant no: 875510); Janssen, Merck KGaA, Merck Sharp and Dohme, Novartis Pharma AG; Pfizer, S{\~a}o Paulo Research Foundation-FAPESP, Takeda and the Wellcome Trust. Additional funding for the SGC-UNC was provided by The Eshelman Institute for Innovation, UNC Lineberger Comprehensive Cancer Center, PharmAlliance, and National Institutes of Health (1R44TR001916-02, 1R01CA218442-01, and 1U24DK116204-01). Support for C.I.W. and D.H.D. also provided by the Foundation for Food and Agriculture Research (FFAR), project A18-2129-S001. Support for I.D. and A.S. provided by DFG, German Reaseach Foundation project 2591307 SFB1177. Funding Information: The Structural Genomics Consortium is a registered charity (no: 1097737) that receives funds from AbbVie; Bayer Pharma AG; Boehringer Ingelheim; Canada Foundation for Innovation; Eshelman Institute for Innovation; Genentech, Genome Canada through Ontario Genomics Institute (OGI-196); EU/EFPIA/OICR/McGill/KTH/Diamond Innovative Medicines Initiative 2 Joint Undertaking (EUbOPEN grant no: 875510); Janssen, Merck KGaA, Merck Sharp and Dohme, Novartis Pharma AG; Pfizer, S?o Paulo Research Foundation-FAPESP, Takeda and the Wellcome Trust. Additional funding for the SGC-UNC was provided by The Eshelman Institute for Innovation, UNC Lineberger Comprehensive Cancer Center, PharmAlliance, and National Institutes of Health (1R44TR001916-02, 1R01CA218442-01, and 1U24DK116204-01). Support for C.I.W. and D.H.D. also provided by the Foundation for Food and Agriculture Research (FFAR), project A18-2129-S001. Support for I.D. and A.S. provided by DFG, German Reaseach Foundation project 2591307 SFB1177. Publisher Copyright: {\textcopyright} 2021 by the authors. Licensee MDPI, Basel, Switzerland. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.",
year = "2021",
month = jan,
day = "2",
doi = "10.3390/ijms22020566",
language = "English (US)",
volume = "22",
pages = "1--18",
journal = "International Journal of Molecular Sciences",
issn = "1661-6596",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "2",
}